US · KPRX
Kiora Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Encinitas, UT 84105
- Website
- kiorapharma.com
Price · as of 2024-12-31
$2.44
Market cap 7.69M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $6.86 | +181.15% |
| Graham-Dodd Method(GD) | $11.29 | +362.83% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $32,400.00 | ||||
| 2015 | $21,492.00 | ||||
| 2016 | $14,472.00 | ||||
| 2017 | $3,088.80 | $10,337.34 | $0.00 | $0.00 | $16,332.03 |
| 2018 | $2,408.40 | $1,422.27 | $0.56 | $0.00 | $0.00 |
| 2019 | $2,001.60 | $4,145.13 | $94,740.99 | $0.00 | $0.00 |
| 2020 | $2,034.00 | $1,463.47 | $7.64 | $0.00 | $5,209.03 |
| 2021 | $206.28 | $307.93 | |||
| 2022 | $33.93 | ||||
| 2023 | $5.89 | ||||
| 2024 | $3.25 | $9.26 | $11.29 |
AI valuation
Our deep-learning model estimates Kiora Pharmaceuticals, Inc.'s (KPRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.44
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.86
+181.15% upside
Graham-Dodd
$11.29
+362.83% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KPRX | Kiora Pharmaceuticals, In… | $2.44 | 7.69M | — | +181% | +363% | — | 3.50 | 0.49 | 0.79 | -2.48 | — | 0.49 | 100.00% | 28.19% | 22.47% | 22.56% | 205.59% | 14.32% | 0.00 | 210.31 | 4.94 | 4.56 | -0.66 | -10359.00% | — | -18949.00% | 67.95% | 1.42 | 613.83% | 0.00% | 0.00% | 11.02% | -3.14 | -1.65 | -0.88 | -3.17 |
| ACXP | Acurx Pharmaceuticals, In… | $1.50 | 2.38M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| ADIL | Adial Pharmaceuticals, In… | $2.53 | 2.43M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| APRE | Aprea Therapeutics, Inc. | $0.92 | 6.41M | +3,789% | +73% | — | — | -0.99 | 0.66 | 8.54 | 0.70 | — | 0.66 | -523.16% | -953.00% | -862.43% | -68.98% | 415.99% | -55.58% | 0.00 | — | 7.01 | 6.80 | 1.60 | -4051.00% | 15763.00% | 1061.00% | -105.72% | -4.03 | 394.27% | 0.00% | 0.00% | 9.68% | 0.70 | 0.74 | -6.66 | -17.99 |
| APVO | Aptevo Therapeutics Inc. | $7.32 | 6.85M | — | — | — | — | -0.03 | 0.15 | — | 0.14 | — | 0.15 | 0.00% | — | — | -284.28% | -3555.20% | -119.36% | 0.97 | — | 1.72 | 1.40 | 0.17 | -9623.00% | — | 10277.00% | -3391.13% | -3.83 | -3437.14% | 0.00% | 0.00% | 0.00% | 0.14 | 0.14 | — | -27.06 |
| BCDA | BioCardia, Inc. | $1.29 | 7.48M | +6,369% | -19% | — | +16,927% | -0.90 | 8.59 | 123.95 | -0.73 | — | 8.59 | -7463.79% | -13794.83% | -13700.00% | 2074.67% | 810.64% | -236.81% | 1.14 | — | 1.13 | 1.02 | 0.18 | -6459.00% | -8784.00% | -1957.00% | -111.72% | -3.46 | 813.78% | 0.00% | 0.00% | 22.70% | -0.72 | -0.72 | 99.47 | -65.68 |
| CELZ | Creative Medical Technolo… | $1.81 | 4.67M | +18,729% | +39% | — | — | -1.12 | 0.97 | 558.52 | -0.04 | — | 1.06 | 60.00% | -52216.92% | -49940.74% | -65.85% | -1515.86% | -63.20% | 0.00 | — | 18.73 | 18.13 | 1.05 | -133.00% | 2222.00% | -3478.00% | -86.29% | -16.18 | -1399.06% | 0.00% | 0.00% | 43.11% | -0.04 | -0.04 | 18.49 | -4.10 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| INAB | IN8bio, Inc. | $1.70 | 7.88M | — | — | — | — | -13.04 | 27.41 | — | -14.50 | — | 27.41 | 0.00% | — | — | -154.44% | -359.44% | -111.38% | 0.35 | — | 4.08 | 3.61 | 0.23 | -4300.00% | — | 131.00% | -6.11% | -7.83 | -286.41% | 0.00% | 0.00% | 0.00% | -12.84 | -16.11 | — | 24.43 |
| PHIO | Phio Pharmaceuticals Corp… | $1.14 | 12.27M | — | — | — | — | -0.14 | 0.22 | — | 0.59 | — | 0.22 | 0.00% | — | — | -114.83% | 1067.49% | -94.69% | 0.00 | — | 5.65 | 5.30 | 0.73 | -9805.00% | — | -3386.00% | -694.83% | -7.01 | 1027.89% | 0.00% | 0.00% | 0.10% | 0.59 | 0.61 | — | -38.36 |
| RNAZ | TransCode Therapeutics, I… | $9.61 | 8.81M | — | — | — | — | -0.93 | -7.75 | — | -0.61 | — | -7.75 | 0.00% | — | — | 8866.96% | 369.89% | -268.85% | -0.02 | -584.07 | 2.56 | 2.10 | 0.36 | -9864.00% | — | -2624.00% | -85.33% | -4.81 | 315.50% | 0.00% | 0.00% | 22.07% | -0.63 | -0.74 | — | -17.50 |
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
- CEO
- Brian Strem
- Employees
- 12
- Beta
- -0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.86 ÷ $2.44) − 1 = +181.15% (DCF, example).